Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 12, 2014, Pages 1349-1362

  Stidham, R W ^a   Lee, T C H ^a   Higgins, P D R ^a   Deshpande, A R ^b   Sussman, D A ^b   Singal, A G ^c   Elmunzer, B J ^a   Saini, S D ^a,d   Vijan, S ^a,d   Waljee, A K ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; PLACEBO;

COMPARATIVE EFFECTIVENESS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BAYES THEOREM; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901497185     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12749     Document Type: Review

References (46)

1. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Schreiber S, Rutgeerts P, Fedorak RN, et al,. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, et al,. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
5. Sandborn WJ, Feagan BG, Stoinov S, et al,. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
6. Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
7. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al,. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
9. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
10. Sandborn WJ, Schreiber S, Feagan BG, et al,. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9: 670-8.e3.
11. Kaymakcalan Z, Sakorafas P, Bose S, et al,. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-16.
12. Nesbitt A, Fossati G, Bergin M, et al,. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-32.
13. Chen JS, Makovey J, Lassere M, Buchbinder R, March LM,. Comparative effectiveness of anti-tumour necrosis factor (TNF) drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken) 2014; 66: 464-72.
14. Kestens C, van Oijen MG, Mulder CL, et al,. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013; 11: 826-31.
15. Osterman MT, Haynes K, Delzell E, et al,. Comparative effectiveness of infliximab and adalimumab for Crohn's Disease. Clin Gastroenterol Hepatol 2014; 12: 811-7.e3.
16. Patil SA, Rustgi A, Langenberg P, Cross RK,. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013; 58: 209-15.
17. Vogelaar L, Spijker AV, van der Woude CJ,. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101-9.
18. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
19. Schoenfeld P, Cook D, Hamilton F, Laine L, Morgan D, Peterson W,. An evidence-based approach to gastroenterology therapy. Evidence-Based Gastroenterology Steering Group. Gastroenterology 1998; 114: 1318-25.
20. van Valkenhoef G, Guobing L, de Brock B, et al,. Automating network meta-analysis. Research Synthesis Methods 2012; 3: 285-99.
21. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P,. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59.
22. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
23. Zorzi F, Zuzzi S, Onali S, et al,. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther 2012; 35: 1397-407.
24. Peyrin-Biroulet L, Laclotte C, Bigard MA,. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25: 675-80.
25. Van Assche G, Vermeire S, Ballet V, et al,. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229-34.
26. Singh S, Nagpal SJ, Murad MH, et al,. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 210-8.
27. Targownik LE, Bernstein CN,. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013; 108: 1835-42.
28. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
29. Du Pan SM, Dehler S, Ciurea A, et al,. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
30. Mahadevan U, Wolf DC, Dubinsky M, et al,. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-92.
31. Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T, investigators Is,. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2013; 38: 52-61.
32. Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM,. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009; 21: 1302-9.
33. Choi GK, Collins SD, Greer DP, et al,. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. J Crohns Colitis 2014; 8: 375-83.
34. Sussman DA, Kubiliun N, Mulani PM, et al,. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012; 18: 2043-55.
35. Chilton F, Collett RA,. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
36. Scarpato S, Antivalle M, Favalli EG, et al,. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 289-94.
37. Sands BE, Ooi CJ,. A survey of methodological variation in the Crohn's disease activity index. Inflamm Bowel Dis 2005; 11: 133-8.
38. Schoepfer AM, Beglinger C, Straumann A, et al,. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.
39. Bouguen G, Levesque BG, Feagan BG, et al,. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013; doi: 10.1016/j.cgh.2013.09.006 [Epub ahead of print].
40. Lewis JD,. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-26.e2.
41. Thorlund K, Druyts E, Avina-Zubieta JA, Wu P, Mills EJ,. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2013; 72: 1524-35.
42. Stidham RW, Lee TC, Higgins PD, et al,. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71.
43. Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK,. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis 2014; doi: 10.1016/j.crohns.2014.01.010 [Epub ahead of print].
44. Coleman CI, Phung OJ, Cappelleri JC, et al,. Use of Mixed Treatment Comparisons in Systematic Reviews. Rockville, MD: AHRQ Methods for Effective Health Care, 2012.
45. Pariente B, Cosnes J, Danese S, et al,. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17: 1415-22.
46. Rimola J, Rodriguez S, Garcia-Bosch O, et al,. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58: 1113-20.